Ghassan K. Abou-Alfa, MD, Discusses Next Steps in Researching Unresectable HCC

Video

Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.

Ghassan K. Abou Alfa, MD, an attending physician at Memorial Sloan Kettering Cancer Center, spoke with CancerNetwork® after the FDA approval of tremelimumab (Imjudo) in combination with durvalumab (Imfinzi) for patients with unresectable hepatocellular carcinoma (HCC) about the next steps in managing the disease. In addition to highlighting the progress that has been made thus far in terms of improving outcomes in patients with HCC, he spotlighted future focuses such as advancing treatment with immune checkpoint inhibitors, as well as combining them with local therapies.

Transcript:

We need to cure [HCC] and we still have ways to go. No question that I humbly and proudly have witnessed this disease start from a median survival of barely 3 months, and worked through different studies at Memorial Sloan Kettering for the last 22 years, and look where we are: We're talking about a mean survival of close to 16.5 months or more. There is no doubt that we are on the right track, but of course, we want more. Why do we need more? We owe our patients that and promise them that. Will there be further advancement of the use of checkpoint inhibitors in a more advanced way? Absolutely. Is it also possible to consider local therapy married with the use of the checkpoint inhibitors? By all means, yes. To that extent, our current study, which is already open in some parts of the world will actually combine chemoembolization for local therapy plus the use of durvalumab and tremelimumab, as we just mentioned.

Reference

Imjudo (tremelimumab) in combination with Imfinzi approved in the US for patients with unresectable liver cancer. News Release. AstraZeneca. October 24, 2022. Accessed October 31, 2022. https://bit.ly/3Fbwx1w

Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Adding radiation to sorafenib elicited a survival improvement in a group of patients with hepatocellular carcinoma, a type of liver cancer.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content
FDA OKs Pembrolizumab/Chemo in HER2- Gastric/GEJ Cancer

FDA OKs Pembrolizumab/Chemo in HER2- Gastric/GEJ Cancer

November 16th 2023
Article

First-line pembrolizumab plus chemotherapy has been approved by the FDA for patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Oncology On-The-Go Podcast: ASCO 2023 Recap

June 19th 2023
Podcast

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Approval of PD-L1 IHC 22C3 pharmDx may also identify patients with non–small cell lung cancer and other malignancies who may benefit from treatment with pembrolizumab.

PD-L1 CDx Earns FDA Approval to Identify PD-L1+ Gastric/GEJ Tumors

November 15th 2023
Article

Approval of PD-L1 IHC 22C3 pharmDx may also identify patients with non–small cell lung cancer and other malignancies who may benefit from treatment with pembrolizumab.

Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, and Colleagues Discuss GOZILA Platform for CRC

Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, and Colleagues Discuss GOZILA Platform for CRC

May 17th 2022
Podcast

Tanios Bekaii-Saab, MD, details the GOZILA platform for colorectal cancer with experts Kristen Ciombor, MD, MSCI, and John Strickler, MD.

Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma following the FDA’s amendment.

FDA Updates Indication for Pembrolizumab in HER2+ Gastric/GEJ Adenocarcinoma

November 9th 2023
Article

Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma following the FDA’s amendment.

CHM 2101 will be assessed as part of a phase 1A/B clinical study in a population of patients diagnosed with advanced colorectal cancer, gastric cancer, and neuroendocrine cancer.

FDA Clears NDA for Novel CDH17 CAR T-Cell Therapy in Advanced GI Cancer

November 8th 2023
Article

CHM 2101 will be assessed as part of a phase 1A/B clinical study in a population of patients diagnosed with advanced colorectal cancer, gastric cancer, and neuroendocrine cancer.